Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Latest Information Update: 11 Jan 2024
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 05 Jan 2024 Planned End Date changed from 1 Mar 2024 to 1 Oct 2026.
- 05 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2026.
- 24 May 2022 Planned End Date changed from 1 Sep 2022 to 1 Mar 2024.